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Accurate and timely diagnosis of dengue virus (DEN) infections is essential for the differential diagnosis of
patients with febrile illness and hemorrhagic fever. In the present study, the diagnostic value of a newly de-
veloped immune-complex dissociated nonstructural-1 (NS-1) antigen dot blot immunoassay (DBI) was com-
pared to a commercially available DEN antigen detection kit (denKEY Blue kit; Globio Co., Beverly, Mass.)
and a reverse transcription-PCR (RT-PCR) kit. Serial serum or plasma samples (n  181) obtained from 55
acute DEN-infected patients were used. In samples obtained from 32 of these 55 DEN-infected patients, viral
RNA could be detected by RT-PCR. DEN antigen was detected in only 10 of these 55 patient samples by using
the denKEY kit. When these samples were treated with acid to release the immune-complex-associated NS-1
antigen for detection by DBI, 43 of these 55 patients were found to be positive for DEN NS-1 antigen. In non-
dissociated samples, 22 of these patients were found to be positive by the DBI. In the presence of DEN-specific
immunoglobulin M antibodies, both viral RNA and DEN (NS-1) antigen could be detected. The number of
positive samples identified by RT-PCR and DBI from these patients with primary DEN infections varied
between 28 and 78%. In secondary DEN infections, the number of samples that tested positive by the DBI after
immune-complex dissociation (DIS-DBI) was 25% higher than the number of samples that tested positive by
RT-PCR and was 35% higher than that determined by nondissociated antigen (NDIS-DBI) detection. We
conclude that the denKEY kit has limited diagnostic value for acute DEN infections compared to the RT-PCR
and the NDIS-DBI and DIS-DBI methods. We clearly demonstrate that in secondary DEN infections the dis-
sociation of NS-1 immune complexes is essential for early diagnosis of DEN infections.
Dengue virus (DEN) is one of the most widespread mosqui-
to-borne human pathogens worldwide, accounting for more
than 50 million infections per year (10). Mosquitoes of the
Aedes species are responsible for transmitting the four sero-
types of DEN (DEN1 to DEN4) to humans. Infection with
DEN may be asymptomatic or may cause a variety of symp-
toms ranging from mild dengue fever (DF) to the more severe
form of dengue hemorrhagic fever (DHF) with or without
shock (dengue shock syndrome [DSS]) (17). In areas where
DEN is endemic, DHF has become an increasingly important
cause of pediatric morbidity and mortality since it was first
described half a century ago (17). Accurate diagnosis of DEN
infections is therefore essential.
The diagnostic methods of choice for the identification of
DEN infections have been the plaque reduction neutraliza-
tion assay and/or virus isolation from patient serum sam-
ples by using mosquito cell lines (17, 18). However, both of
these assays are laborious to perform and a period of at least
7 days is required to obtain accurate diagnostic results using
them. Recently, several enzyme-linked immunosorbent assays
(ELISAs) have become commercially available for the detec-
tion of DEN-specific antibodies of different isotypes (6, 7).
However, DEN serology is not virus specific but shows a high
amount of cross-reactivity with other flaviviruses (8). Detection
of viral RNA in serum samples from acute-phase DEN-in-
fected patients by using a reverse transcription-PCR (RT-
PCR) has been described and is a valuable tool for both diag-
nosis of DEN infections and the identification of the viral
serotype (11). RT-PCR provides an accurate diagnosis for
DEN infections during the early stages of DEN illness, even in
the presence of DEN-specific immunoglobulin M (IgM) anti-
bodies (2). The RT-PCR is, however, relatively expensive to
use as a routine diagnostic test and requires specialized labo-
ratory equipment and trained personnel. In addition, the stor-
age of the serum samples at 70°C that is essential for RT-
PCR in order to maintain viral RNA in optimal conditions is
not feasible in many areas where DEN is endemic. As an
alternative, the detection of viral antigens has been proposed
(19) and a suitable ELISA (12) can be performed with patient
serum samples that have been stored at 4°C. A simplified
immunoassay for the detection of DEN antigen in patient
samples with a sensitivity and specificity comparable to the
RT-PCR would therefore be highly desirable. The DEN non-
structural-1 (NS-1) protein has been identified as either an
intracellular membrane-associated protein or a soluble extra-
cellular protein (3). Since high concentrations of the NS-1
protein were found in blood samples of patients obtained dur-
ing the early acute phase of both primary and secondary DEN
infections and for up to 9 days after the onset of symptoms (1),
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DEN NS-1 detection assays are likely to be valuable diagnostic
tools. Anti-NS-1 antibodies were rarely detected by immu-
noblot assays in samples from patients with primary DEN
infections, but these antibodies were detected much more
frequently in patients with secondary DEN infections, in par-
ticular among patients from areas where DHF and DSS is
more frequent (such as Indonesia), compared to patients from
areas where DHF and DSS is not so common (such as the
Caribbean) (10).
Dissociation of antibody-antigen (Ab-Ag) immune com-
plexes has proven to be important for the early diagnosis of
several blood-borne viruses such as human immunodeficiency
virus and both hepatitis B and C viruses (13, 14, 16). This
technique has not, however, been applied in the diagnosis of
flavivirus infections and in particular for DEN infections.
In the present study, we assessed the diagnostic value of dis-
sociated and nondissociated DEN NS-1 Ab-Ag immune com-
plexes in samples from primary and secondary DEN patients
by using a dot blot immunoassay (DBI). The results were com-
pared to a commercially available DEN antigen detection kit
(denKEY Blue; Globio Co., Beverly, Mass.) and DEN-specific
RT-PCR.
MATERIALS AND METHODS
Serum and plasma samples. Serial serum and plasma samples were collected
from January 2000 to March 2002 from 55 patients with acute DEN infections
and stored in aliquots at80°C until use. The diagnosis of the patients was based
on the clinical and serological criteria set by the World Health Organization (17).
Thirty-nine patients were from Indonesia, and plasma samples (n  156) were
obtained upon admission to the hospital (D0) and on days 1, 2, and 7 postad-
mission (D1, D2, and D7, respectively). All of these Indonesian patients were
children; 20 of them were suffering from DSS. Twenty-five serum samples were
obtained from 16 patients from the Dutch Antilles. From nine of these patients,
serum samples were obtained upon presentation to their treating physician (D0)
and also 2 weeks later (D14), whereas from the remaining seven patients only
one serum sample was available obtained upon presentation to the clinic (D0).
The patients from the Antilles were all adults with DF. In all, 18 patients had
primary DEN infections and 37 patients had secondary DEN infections based on
their serological profiles (17). Sixteen serum samples were obtained from healthy
Dutch blood donors with no evidence of current or previous DEN infection (as
defined by the absence of DEN specific IgM and/or IgG antibodies) served as the
negative controls.
IgM and IgG ELISA. A commercially available kit (Focus Technologies, Cy-
press, Calif.) was used for the detection of DEN-specific IgM and IgG antibodies
in the samples and performed according to the procedures described by the
manufacturer. The sensitivity and specificity of the assays has been described
elsewhere (6).
Dot blot assay. Patient serum or plasma samples were diluted either 1:3 in
phosphate-buffered saline (PBS) (nondissociated samples) or 1:2 in dissociation
buffer (1.5 M glycine [pH 2.8]). Ab-Ag immune complexes were dissociated for
1 h at 37°C, and the reaction was stopped by the addition of 1 volume of
neutralization buffer (1.5 M Tris-HCl [pH 9.7]) to achieve an end dilution of 1:3
for the sample. The samples were then spotted onto nitrocellulose membranes
(High Bond-P membranes; Amersham Biosciences, Little Chalfont, United
Kingdom). After the samples were spotted onto nitrocellulose, the membranes
were air dried, treated with methanol containing 0.3% H2O2, washed with dis-
tilled water and PBS, and blocked overnight at 4°C with 5% skimmed milk (ELK
Campina, Eindhoven, The Netherlands) in PBS containing 0.1% Tween 20
(PBS-T). The blots were then washed with PBS-T and incubated for 30 min at
room temperature with monoclonal antibody 3D1.4, which defines the LX1
epitope on the NS-1 proteins of each DEN serotype (4), diluted in PBS-T buffer
containing 5% skimmed milk, 5% normal goat serum (ICN Biochemicals, Inc.,
Cleveland, Ohio), 5% fetal bovine serum (ICN Biochemicals, Inc.), and 20%
normal human serum (blot buffer). The blots were then washed thoroughly for 30
min with PBS-T and incubated for 30 min at room temperature with goat
anti-mouse horseradish peroxidase conjugate (Dako, Glostrup, Denmark) di-
luted 1:10,000 in blot buffer. The blots were washed, incubated in PBS for 5 min,
and further processed with the ECL substrate system (ECL; Amersham Bio-
sciences) according to the procedures described by the manufacturer. Films
(Kodak X-Omat AR) were exposed for 5 min before development.
DEN antigen detection ELISA. The presence of DEN antigen in the serum and
plasma samples was measured by using a newly described, commercially available
kit (Globio Co.) based on an ELISA method according to the procedures of the
manufacturer. Briefly, diluted samples are incubated for 2 h in microtiter wells,
followed by a 1-h incubation step with a DEN-specific antibody. When DEN
antigen was present in the serum samples, it was bound by the detecting anti-
body, and the Ab-Ag immune complexes were then detected after the addition
of an enzyme-labeled conjugate and subsequent substrate reaction.
Detection of viral RNA. DEN RNA was isolated from 200 l of patients’ serum
or plasma by using the High-Pure RNA extraction kit (Roche, Mannheim,
Germany) according to the procedure described by the manufacturer. DEN
serotype-specific reverse transcriptase, followed by PCR (i.e., RT-PCR) was
performed as described previously (11, 15). Patient samples were considered
positive when a band of the correct size (DEN1, 482 bp; DEN2, 119 bp; DEN3,
290 bp; and DEN4, 392 bp) was observed by using a UV illuminator after 2%
agarose gel electrophoresis and subsequent staining with ethidium bromide.
Calculations. For the determination of DEN-specific IgM and IgG antibody
ratios, the cutoff values provided by the manufacturer were used. Samples were
considered positive with the dot blot assay when a clear spot could be visualized
on films, in the absence of signal in the conjugate control. Readings of the dot
blot assays (i.e., the DBI) were performed by two independent observers. Sam-
ples were considered positive by using the denKEY kit, based on the criteria of
the manufacturer, when an optical density value of 0.150 was obtained.
RESULTS
Detection of DEN NS-1 antigen in dissociated and nondis-
sociated samples. The DEN NS-1 detection sensitivity of the
DBI was higher when the patient samples were treated with
acid to dissociate their Ab-Ag immune complexes, as shown in
Fig. 1. Of the 181 samples tested by the DBI, DEN NS-1
antigen could be detected in only 32 of them without Ab-Ag
dissociation (NDIS-DBI), whereas this antigen could be de-
FIG. 1. Detection of DEN NS-1 antigen with the DBI in serum or
plasma samples after dissociation (DIS) of immune complexes or with-
out dissociation (NDIS) of immune complexes. pc Ag, positive control
(DEN antigen); nc Ag, negative control antigen; nc, negative control
human serum. Acetone-extracted positive and negative antigen con-
trols were prepared as previously described (7).
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tected in 113 of these samples after acid treatment (DIS-DBI).
Of the 32 NDIS-DBI-positive samples, 24 were also positive in
the DIS-DBI.
Detection of DEN antigen in the presence of DEN-specific
IgM antibodies. The DEN antigen detection level of the
denKEY kit was low, since only 10 of the 181 patient samples
had optical density values higher than the cutoff value. Nine of
the ten denKEY antigen-positive patients were positive on day
0 after admission to the hospital, whereas one patient was
DEN antigen positive on day 7 after admission to the hospital.
The denKEY kit identified DEN antigen in five patients with
primary DEN infections and five patients with secondary DEN
infections (Table 1). There was no correlation between the
very low DEN antigen detection levels in these patient samples
obtained with this assay and the presence of DEN-specific IgM
antibodies in these samples (Fig. 2), although most of these
DEN-antigen positive samples had relatively low or negative
titers to IgM antibodies.
The DEN antigen detection level of the DBI was signifi-
cantly higher than that obtained by using the denKEY kit,
especially when samples were treated to dissociate immune
complexes (DIS-DBI). In 22 of the 55 DEN-infected patients,
DEN NS-1 antigen could be detected by the DBI without the
dissociation step being necessary. Of these patients, 12 were
experiencing primary DEN infections and 10 were experienc-
ing secondary DEN infection (Table 1). When the patient
samples were dissociated, 43 of them were found to be positive
for DEN NS-1 antigen; 14 of these had primary DEN infec-
tions and 29 had secondary DEN infections (Table 1). Detec-
tion of DEN NS-1 antigen was not influenced by the presence
of DEN-specific IgM antibodies when evaluated with NDIS-
DBI or DIS-DBI (Fig. 2).
Detection of DEN NS-1 antigen in patients’ samples from
different areas where DEN is endemic. The DEN NS-1 antigen
detection level determined by NDIS-DBI in samples from pa-
tients with primary DEN infection was similar for patients
from Indonesia (64%) or from the Dutch Antilles (72%). The
DEN NS-1 antigen detection level was increased in samples
from primary-DEN-infection Indonesian patients (91%) but
slightly reduced in samples from primary-DEN-infection An-
tillean patients (57%) when tested by DIS-DBI (Table 2). In
samples obtained from patients with secondary DEN infec-
tions, the DEN NS-1 antigen detection levels were low among
Antillean samples: 44% with the NDIS-DBI and 33% with the
DIS-DBI. In contrast, the detection level of DEN NS-1 antigen
in samples from Indonesian patients with secondary DEN in-
fections increased dramatically from 22% with the NDIS-DBI
to 93% with the DIS-DBI (Table 2).
Comparison of DEN type-specific RT-PCR and DEN anti-
gen detection assays. A comparison of DEN antigen and viral
RNA detection with the denKEY kit, the DBI, and RT-PCR in
serially collected samples obtained from patients who lived in
areas where DEN is endemic is shown in Fig. 3. Using the
RT-PCR, DEN RNA was detected in 32 of the 55 patients with
acute DEN infections. Eight patients were infected with DEN1
(seven Indonesian patients and one Antillean patient), four
patients were infected with DEN2 (all Indonesian patients),
nineteen patients were infected with DEN3 (four Indonesian
and fifteen Antillean patients), and one patient from Indonesia
was infected with DEN4 (Table 3). All but one of the 32
RT-PCR-positive patients were positive on day 0 (the day of
first presentation to the clinician), whereas five patients re-
mained positive for viral RNA on days 1 and 2 postadmission
to the hospital. Only one patient was positive by RT-PCR on
day 7 after admission to the hospital (Fig. 3). Of the 16 RT-
PCR-positive Indonesian patients for whom clinical records
were available, 6 patients had DSS, while 10 had DHF.
FIG. 2. Detection of DEN NS-1 antigen and viral RNA with dif-
ferent assays compared to the levels of DEN-specific IgM antibodies in
samples obtained from patients with acute DEN infection. The z axis
represents the number of positive patients with each assay from sam-
ples obtained on day 0.
TABLE 1. Detection of DEN NS-1 antigen and viral RNA in
patients with primary or secondary DEN infections
Assaya
No. of positive samples (% of total)
Primary infections
(n  18)
Secondary infections
(n  37)
Total
(n  55)
denKEY kit 5 (28) 5 (13) 10 (18)
RT-PCR 12 (67) 20 (54) 32 (58)
NDIS-DBI 12 (61) 10 (27) 22 (40)
DIS-DBI 14 (77) 29 (78) 43 (78)
a NDIS, samples not treated with acid for dissociation of Ab-Ag immune
complexes; DIS, samples treated for dissociation of Ab-Ag immune complexes.
TABLE 2. Detection of DEN NS-1 antigen by using NDIS-DBI
and DIS-DBI in samples obtained from Indonesian and Antillean
patients with primary and secondary DEN infectionsa
Infection
type
No. of positive
Indonesian samples
(n  39)b (% of total)
No. of positive
Antillean samples
(n  16)c (% of total)
NDIS DIS NDIS DIS
Primary 7 (64) 10 (91) 5 (72) 4 (57)
Secondary 6 (22) 26 (93) 4 (44) 3 (33)
a See Table 1, footnote a.
b Eleven primary and twenty-eight secondary infections.
c Seven primary and nine secondary infections.
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Using the denKEY kit, DEN antigen was detected in 1 of
the 8 DEN1-infected patients, in none of the DEN2-infected
patients, in 8 of the 19 DEN3-infected patients, and in the
single DEN4-infected patient (serotypes were determined by
RT-PCR). The one patient who was found to be positive by the
RT-PCR on day 7 after admission to the hospital was also
found to be positive with the denKEY kit (Table 3).
Using the NDIS-DBI, DEN NS-1 antigen was detected in 6
of the 8 DEN1-infected patients, in 1 of the 4 DEN2-infected
patients, in 10 of the 19 DEN3-infected patients, and in the
single DEN4-infected patient. After dissociation of the pa-
tients’ immune complexes (DIS-DBI), DEN NS-1 antigen was
detected in 6 of the 8 DEN1-infected patients, in all 4 DEN2-
infected patients, in 11 of the 19 DEN3-infected patients, and
in the DEN4-infected patient (Table 3). In addition, DEN
NS-1 antigen was detected by NDIS and DIS-DBI in 19 pa-
tients, who were found to be negative by the RT-PCR for the
presence of viral RNA (Fig. 3).
Overall comparison. Table 4 summarizes the overall com-
parison of the DEN (NS-1) antigen detection assays and the
RT-PCR for the 181 serum and plasma samples tested. A total
of 42 serum samples tested positive for the presence of viral
RNA by using the RT-PCR; of these, only 10 (23%) tested
positive with the denKEY kit, 23 (55%) tested positive with the
NDIS-DBI, and 28 (67%) tested positive with the DIS-DBI.
All of the 139 serum samples that tested negative with the
RT-PCR were also negative with the denKEY kit; 130 (93%)
tested negative with the NDIS-DBI, whereas only 54 (39%)
tested negative with the DIS-DBI (Table 4).
DISCUSSION
Routine diagnosis of DEN infections is mainly based on
serological assays for the detection of DEN-specific IgM and
IgG antibodies. Detecting DEN antigen in serum and plasma
samples with a simple, rapid, and easy-to-perform assay, such
as an ELISA or a dot blot assay with a sensitivity and specificity
similar to that of the RT-PCR, would be an excellent alterna-
tive for routine diagnosis of acute DEN infections.
In the present study we describe a DBI for the detection of
the DEN NS-1 antigen, since high concentrations of this anti-
gen were previously shown to be present in patient samples
obtained during the early acute phase of either primary or
secondary DEN infections (1, 19). Since antibodies to the
DEN NS-1 protein are generated, particularly during second-
ary DEN infections in patients from Indonesia (an area where
DHF and/or DSS is common) compared to the DEN infections
in patients from Puerto Rico (an area where DHF and/or DSS
is less common) (9), we also chose to compare the relative
sensitivities of these assays in both primary and secondary
DEN infections in patients from Indonesia and the Dutch
Antilles before and after dissociation of the immune com-
plexes. The predominant DEN serotype circulating during the
outbreaks in Indonesia and the Dutch Antilles was DEN3 (5).
FIG. 3. Kinetics of DEN NS-1 antigen and viral RNA detected with
the different assays on different time points after the onset of illness.
Day 0 is the day of presentation to the clinic and represents days 3 to
6 after the onset of illness.
TABLE 3. Comparison of methods for detection of viral antigen
(denKEY antigen kit and DBI) versus viral RNA (RT-PCR)
in samples obtained from 55 DEN-infected patients
Method
No. of samples positive by RT-PCR
(n  number of positive patients) for:
DEN1
(n  8)
DEN2
(n  4)
DEN3
(n  19)
DEN4
(n  1)
Total
(n  32)
denKEY kit 1 0 8 1 10
NDIS-DBI 6 1 10 1 18
DIS-DBI 6 4 11 1 22
Total NDIS and DIS-DBI 8 4 14 1 27
a NDIS, nondissociated samples; DIS, Ab-Ag immune complex-dissociated
samples.
TABLE 4. Overview of the results for the detection of DEN NS-1
antigen and viral RNA in 181 samples from DEN-infected patients
by using the denKEY kit, the DBI, and RT-PCR
Method Scorea
No. of positive samples as
determined by:
RT-PCR
DEN NS-1 DBIb
NDIS DIS
denKEY kit  10 9 6
 0 1 4
 32 24 107
 139 147 64
NDIS-DBI  23 25
 9 7
 19 88
 130 61
DIS-DBI  28 25
 85 88
 14 7
 54 61
a , sample scored positive in the respective test;, sample scored negative in
the respective test.
b NDIS, nondissociated samples; DIS, dissociated samples.
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All patients from Indonesia were children with DHF and/or
DSS, whereas the patients from the Antilles were all adults
with symptoms of DF. For our assay, we used a monoclonal
antibody (3D1.4) that detects the minimal peptide sequence
YSWKTWG, which is present in the NS-1 proteins of three
DEN serotypes. The potentially higher specificity of this mono-
clonal antibody for the NS-1 protein of DEN1 was not, how-
ever, reflected in the relative NS-1 detection sensitivities for
the other DEN serotypes (4). This monoclonal antibody was
more reactive with the corresponding sequence from the NS-1
protein of DEN1, which contained a single amino acid substi-
tution (YSWKSWG) (4).
In the present study, we demonstrated that nondissociated
DEN NS-1 antigen was detected in 61% of DEN primary cases
compared to 27% detection of the secondary cases (Table 1).
Furthermore, we demonstrated that nondissociated DEN NS-1
antigen was detected in the majority of the patients with pri-
mary DEN infection from Indonesia and the Dutch Antilles
but could be further increased in the Indonesian patient sam-
ples with the DIS-DBI. Dissociation of DEN NS-1 Ab-Ag
immune complexes proved to be essential for the detection of
DEN NS-1 antigen in serum and plasma samples, particularly
among samples obtained from Indonesian patients with sec-
ondary DEN infections since the sensitivity of the DBI in-
creased dramatically (up to 93%) when these dissociated sam-
ples were tested. These results are in agreement with those of
a previous study in which it was demonstrated that anti-NS-1
antibodies are mainly generated during secondary DEN infec-
tions in patients from Indonesia (where DHF and/or DSS is
more common) than in patients from the Caribbean (where
DHF and/or DSS is not common) (10). These preexisting anti-
NS-1 antibodies possibly result from the formation of Ab-Ag
immune complexes and therefore reduce the sensitivity of the
DEN NS-1 antigen detection assay, in particular when the
NDIS-DBI is used.
The sensitivity of the denKEY kit was very poor, since only
10 samples tested positive for the presence of DEN antigen
with this assay. However, both the denKEY kit and DBI of
nondissociated samples detected DEN NS-1 antigen with
greater sensitivity in samples from primary infections, whereas
DBI of dissociated samples detected DEN NS-1 antigen with
the same sensitivity in samples from either primary or second-
ary infections. In a previous study it was demonstrated that
DEN viral RNA could be detected in the presence of DEN-
specific IgM antibodies in serum or plasma samples of DEN-
infected patients (2). In our study we confirmed these results
and, furthermore, we demonstrated that DEN NS-1 antigen
could also be detected in the presence or absence of DEN-
specific IgM antibodies. However, the number of NS-1 anti-
gen-positive patients in the presence of IgM was significantly
higher in dissociated samples at different levels of IgM anti-
bodies (Fig. 2).
We also studied the number of DEN antigen-positive pa-
tients at several time points after infection. Recently, it was
demonstrated that DEN NS-1 antigen could be detected be-
tween days 0 and 9, with a slight peak on day 4 after the onset
of illness (1). Our findings are in agreement with this previous
study since we demonstrated that the majority of positive sam-
ples for DEN NS-1 antigen were obtained in patients between
days 0 and 2 after admission to the hospital (i.e., 3 to 6 days
after the onset of symptoms). Furthermore, we were able to
detect the DEN NS-1 antigen with the DBI during the early
convalescent phase of DEN illness in 15 of the 55 DEN pa-
tients (Fig. 3). Viral antigens circulate in patients’ blood for
longer periods than viral RNA, and we were therefore able to
detect DEN NS-1 antigen in many patient samples in which
viral RNA was not detectable (i.e., RT-PCR negative). The
results we obtained with the RT-PCR showed that the highest
percentage of positive samples was detected on day 0 in both
cohorts (97%). However, on days 1 to 7 RT-PCR-positive
results were also obtained.
The specificity of the DEN NS-1 antigen detection DBI did
not seem to be influenced by the infecting DEN serotype. In
contrast, the denKEY kit seems to detect DEN 3 with a higher
sensitivity (43% of the DEN3-infected patients were also
found to be positive with the denKEY kit) than the other three
serotypes. However, it is difficult to draw any reliable conclu-
sions about the serotype specificity of the assays. Our sample
size of DEN-positive patients with the RT-PCR was rather
small, and there was not a similar incidence of each of the four
DEN serotypes among our patients (e.g., we were able to
detect DEN4 viral RNA in only one patient). We could not,
therefore, perform a statistical analysis on the serotype speci-
ficity of the DEN NS-1 antigen detection assays in more detail.
Furthermore, based on the clinical data available, we were not
able to find any significant differences associated with disease
severity and the presence of DEN NS-1 antigens in acute-
and/or convalescent-phase samples.
In conclusion, we demonstrated here that the combination
of NS-1 antigen detection by DBI in both nondissociated and
dissociated serum and plasma samples from primary and sec-
ondary cases of DEN infection results in the highest number of
DEN antigen-positive patients versus the RT-PCR and the
denKEY kit. We also showed that dissociation of immune
complexes is essential for the detection of DEN NS-1 protein
in secondary cases of DEN infection. This newly developed
method also offers the opportunity for rapid identification of
dengue infections among many other flavivirus circulating in
areas where DEN is endemic and causing similar clinical symp-
toms; this method also overcomes several problems associated
with the RT-PCR approach. For example, patient serum or
plasma samples could be adequately stored at 4°C for subse-
quent testing with this assay since the DEN NS-1 antigen is
more stable than viral RNA, and the problems due to contam-
ination of RT-PCR products are also not an issue in antigen
detection assays. In addition, DBI is rapid, easy to perform,
and can be carried out in less-well-equipped laboratory set-
tings. The high sensitivity of the DBI in detecting DEN NS-1
antigen in samples from acute primary or secondary DEN
infection patients make it a valuable diagnostic tool and a good
alternative to the RT-PCR. In contrast, we found the denKEY
kit to be unsuitable for DEN virus diagnosis due to its low
sensitivity.
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